SCHEMBL23384172

SCHEMBL23384172

C=C(CCNC(=O)COc1ccc(Cl)cc1)NC(=O)CCC

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.49
▸ KMT2A Q03164 5/20 0.49
▸ HTT P42858 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ HDAC1 Q13547 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ TSHR P16473 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ NPY1R P25929 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ BCHE P06276 1/20 0.45
▸ ACHE P22303 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23383779 0.91 MEN1 (0.50) MEN1KMT2AHTTKDM4ESMN1; SMN2
SCHEMBL23182908 0.91 KDM4E (0.54) MEN1KMT2AHTTKDM4ESMN1; SMN2
SCHEMBL23383882 0.89 KDM4E (0.48) MEN1KMT2AHTTKDM4ESMN1; SMN2
SCHEMBL23383874 0.89 TSHR (0.47) MEN1KMT2AHTTKDM4ESMN1; SMN2
SCHEMBL23383996 0.88 MEN1 (0.50) MEN1KMT2AHTTKDM4ESMN1; SMN2
SCHEMBL23182881 0.88 HDAC1 (0.61) MEN1KMT2AHTTKDM4ESMN1; SMN2
SCHEMBL23384162 0.88 KMT2A (0.49) MEN1KMT2AHTTKDM4ESMN1; SMN2
SCHEMBL23383744 0.88 HTT (0.57) MEN1KMT2AHTTKDM4ESMN1; SMN2
SCHEMBL23383778 0.87 MEN1 (0.47) MEN1KMT2AHTTKDM4ESMN1; SMN2
SCHEMBL23383781 0.87 MEN1 (0.48) MEN1KMT2AHTTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210145771-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210145771-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES ATF4, EIF2B1, EIF4A1 MEN1 4354/4885KMT2A 2778/4885HTT 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback